Aura Biosciences names Natalie Holles CEO; CoMpass trial enrollment at 86 patients, nearing completion

Aura Biosciences, Inc.

New CEO Natalie Holles, former CEO of Third Harmonic Bio and Audentes, appointed effective April 30, 2026.
Founder Elisabet de los Pinos steps down as CEO and director; remains as consultant through October 2026.
Phase 3 CoMpass trial for bel-sar in early choroidal melanoma has 86 patients enrolled; >25 additional patients identified for screening.
Company reiterates guidance: enrollment completion by mid-2026, topline data in H2 2027.
ATM prospectus terminated; $6.7M gross proceeds raised from 1.06M shares sold.

item 5.02 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Elisabet de los Pinos

Chief Executive Officer and President

AURA · Aura Biosciences, Inc.

Effective: 2026-04-30
Successor: Natalie Holles
Filed: May 4, 2026, 7:59 PM ET

Dr. Elisabet de los Pinos, the Company’s founder, who has notified the Company of her departure from her role at the Company as Chief Executive Officer and President and as a director of the Company, effective as of the Effective Date

Departed

Elisabet de los Pinos

Director

AURA · Aura Biosciences, Inc.

Effective: 2026-04-30
Filed: May 4, 2026, 7:59 PM ET

notified the Company of her departure from her role at the Company as Chief Executive Officer and President and as a director of the Company, effective as of the Effective Date

Appointed

Natalie Holles

Chief Executive Officer and President

AURA · Aura Biosciences, Inc.

Effective: 2026-04-30
Successor: Natalie Holles
Filed: May 4, 2026, 7:59 PM ET

the Board of Directors (the “Board”) of Aura Biosciences, Inc. (the “Company”) appointed Natalie Holles as the Company’s Chief Executive Officer and President and as a Class I director with a term expiring at the Company’s 2028 annual meeting of stockholders, effective as of April 30, 2026

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Elisabet de los Pinos departed as Chief Executive Officer and President at Aura Biosciences, Inc..

Action: departed
Role: Chief Executive Officer and President

Exact text from the filing

Dr. Elisabet de los Pinos, the Company’s founder, who has notified the Company of her departure from her role at the Company as Chief Executive Officer and President and as a director of the Company, effective as of the Effective Date

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Elisabet de los Pinos departed as Director at Aura Biosciences, Inc..

Action: departed
Role: Director

Exact text from the filing

notified the Company of her departure from her role at the Company as Chief Executive Officer and President and as a director of the Company, effective as of the Effective Date

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Natalie Holles was appointed as Chief Executive Officer and President at Aura Biosciences, Inc..

Action: appointed
Role: Chief Executive Officer and President

Exact text from the filing

the Board of Directors (the “Board”) of Aura Biosciences, Inc. (the “Company”) appointed Natalie Holles as the Company’s Chief Executive Officer and President and as a Class I director with a term expiring at the Company’s 2028 annual meeting of stockholders, effective as of April 30, 2026

View on SEC.gov

Aura Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-202414

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.